Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
TBPH Theravance Biopharma, Inc. daily Stock Chart
TBPH [NASD]
Theravance Biopharma, Inc.
Healthcare | Biotechnology | Cayman Islands
statements
Index- P/E- EPS (ttm)-4.73 Insider Own5.40% Shs Outstand63.30M Perf Week-9.73%
Market Cap1.03B Forward P/E- EPS next Y-3.01 Insider Trans-1.21% Shs Float51.70M Perf Month-16.56%
Income-285.20M PEG- EPS next Q-1.03 Inst Own84.70% Short Float6.82% Perf Quarter-9.53%
Sales82.60M P/S12.53 EPS this Y-6.50% Inst Trans-0.32% Short Ratio9.37 Perf Half Y-35.36%
Book/sh-4.13 P/B- EPS next Y33.40% ROA-54.60% Target Price- Perf Year-10.43%
Cash/sh5.62 P/C2.89 EPS next 5Y6.70% ROE134.90% 52W Range14.48 - 31.54 Perf YTD-37.31%
Dividend- P/FCF- EPS past 5Y10.60% ROI-106.70% 52W High-48.54% Beta1.02
Dividend %- Quick Ratio4.30 Sales past 5Y44.40% Gross Margin- 52W Low12.09% ATR1.10
Employees316 Current Ratio4.30 Sales Q/Q47.60% Oper. Margin- RSI (14)40.24 Volatility5.50% 6.49%
OptionableYes Debt/Eq- EPS Q/Q-11.20% Profit Margin- Rel Volume0.97 Prev Close17.21
ShortableYes LT Debt/Eq- EarningsNov 05 AMC Payout- Avg Volume376.34K Price16.23
Recom2.20 SMA20-11.58% SMA50-7.70% SMA200-25.29% Volume366,198 Change-5.69%
Oct-14-20Upgrade Morgan Stanley Equal-Weight → Overweight $32
Jul-07-20Initiated JP Morgan Overweight $29
Jun-15-20Initiated Morgan Stanley Equal-Weight $30
May-13-20Initiated Cowen Outperform $42
Jan-08-20Reiterated H.C. Wainwright Buy $25 → $30
Nov-06-19Upgrade Robert W. Baird Underperform → Neutral $22 → $18
Oct-29-19Initiated H.C. Wainwright Buy $25
Mar-29-18Resumed Piper Jaffray Overweight $45
Aug-17-17Initiated Evercore ISI Outperform $45
Jun-16-17Initiated Cantor Fitzgerald Overweight $55
May-11-17Reiterated Needham Buy $40 → $45
Dec-21-16Initiated Needham Buy $40
Nov-03-16Initiated Piper Jaffray Overweight
Oct-12-16Downgrade Robert W. Baird Neutral → Underperform $19 → $24
Aug-03-16Downgrade BofA/Merrill Neutral → Underperform
Jun-20-16Reiterated Leerink Partners Outperform $26 → $29
Jun-20-16Initiated Guggenheim Buy $30
May-12-16Initiated Leerink Partners Outperform $26
May-05-16Downgrade BofA/Merrill Buy → Neutral
Feb-03-15Upgrade Robert W. Baird Underperform → Neutral $13 → $17
Nov-17-20 06:00AM  
Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference
PR Newswire
Nov-09-20 12:17PM  
Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line
Zacks +6.40%
10:20AM  
Analysts Have Lowered Expectations For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Its Latest Results
Simply Wall St.
Nov-07-20 01:31AM  
Theravance Biopharma Inc (TBPH) Q3 2020 Earnings Call Transcript
Motley Fool
Nov-05-20 07:05PM  
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
Zacks
03:30PM  
Theravance Biopharma, Inc. to Host Earnings Call
ACCESSWIRE
Oct-29-20 12:34PM  
Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Zacks
Oct-27-20 01:19PM  
Would Shareholders Who Purchased Theravance Biopharma's (NASDAQ:TBPH) Stock Three Years Be Happy With The Share price Today?
Simply Wall St.
Oct-22-20 06:00AM  
Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020
PR Newswire +5.31%
Oct-19-20 10:39AM  
Hedge Funds Have Never Been This Bullish On Theravance Biopharma Inc (TBPH)
Insider Monkey
Sep-05-20 11:31AM  
Why Is Theravance Bio (TBPH) Down 17.7% Since Last Earnings Report?
Zacks
Sep-01-20 06:00AM  
Theravance Biopharma to Present at Upcoming Investor Conferences
PR Newswire
Aug-07-20 01:27PM  
Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2
Zacks -13.82%
Aug-06-20 06:35PM  
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Zacks
04:34PM  
Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
PR Newswire
Jul-30-20 12:34PM  
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
Jul-27-20 06:00AM  
Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020
PR Newswire
Jul-22-20 12:32PM  
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks
Jul-02-20 06:00AM  
Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors
PR Newswire
Jun-29-20 03:50PM  
Hedge Funds Have Never Been More Bullish On Theravance Biopharma Inc (TBPH)
Insider Monkey
Jun-26-20 12:04PM  
Theravance Doses First Patient in Phase II Coronavirus Study
Zacks
Jun-25-20 08:26AM  
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
Benzinga
06:00AM  
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
PR Newswire
Jun-17-20 09:38PM  
GSK Finance (No.3) plc -- Moody's assigns A2 rating to GSK Finance (No.3) plc's proposed exchangeable notes
Moody's -9.05%
Jun-15-20 09:57AM  
Benzinga's Top Upgrades, Downgrades For June 15, 2020
Benzinga -6.61%
Jun-05-20 11:31AM  
Theravance Bio (TBPH) Down 2.7% Since Last Earnings Report: Can It Rebound?
Zacks
Jun-02-20 09:02PM  
Edited Transcript of TBPH earnings conference call or presentation 6-May-20 9:00pm GMT
Thomson Reuters StreetEvents
May-08-20 02:31PM  
Theravance Biopharma Inc (TBPH) Q1 2020 Earnings Call Transcript
Motley Fool
May-07-20 01:57PM  
Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates
Zacks
May-06-20 07:35PM  
Theravance Biopharma (TBPH) Reports Q1 Loss, Tops Revenue Estimates
Zacks
Apr-29-20 12:33PM  
Will Theravance Biopharma (TBPH) Report Negative Earnings Next Week? What You Should Know
Zacks
Apr-28-20 12:33PM  
Will Theravance Biopharma (TBPH) Report Negative Q1 Earnings? What You Should Know
Zacks
10:35AM  
Here's What We Think About Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pay
Simply Wall St.
06:00AM  
Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020
PR Newswire
Apr-23-20 06:00AM  
Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
PR Newswire
Apr-20-20 06:00AM  
Theravance Biopharma Announces Peer-Reviewed Publication Highlighting TD-1473 Program in the Journal of Crohn's and Colitis
PR Newswire
Apr-14-20 04:41PM  
Seth Klarman Dials Down Akebia Therapeutics Stake
GuruFocus.com
Apr-09-20 07:00AM  
Theravance Biopharma Responds to COVID-19 Pandemic by Advancing TD-0903 to Treat Hospitalized Patients with Acute Lung Injury
PR Newswire +5.11%
Mar-25-20 11:30AM  
Theravance Bio (TBPH) Up 2.1% Since Last Earnings Report: Can It Continue?
Zacks -5.40%
Mar-23-20 06:32PM  
Stocks To Watch: Theravance Biopharma Sees Relative Strength Rating Jump To 94
Investor's Business Daily
Mar-20-20 08:02PM  
Seth Klarman Sees Bargains as the Market Heads Further Into Chaos
GuruFocus.com
Mar-02-20 07:00AM  
Theravance Biopharma Announces Closing of Private Placement of $400 Million Non-Recourse Notes
PR Newswire
Feb-27-20 02:49PM  
Analysts Have Lowered Expectations For Theravance Biopharma, Inc. After Its Latest Results
Simply Wall St.
Feb-25-20 02:53PM  
Theravance (TBPH) Q4 Earnings Miss, Revenues Beat Estimates
Zacks
02:06AM  
Edited Transcript of TBPH earnings conference call or presentation 24-Feb-20 10:00pm GMT
Thomson Reuters StreetEvents
Feb-24-20 06:15PM  
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates
Zacks -8.77%
Feb-18-20 07:00AM  
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
PR Newswire
Feb-17-20 12:30PM  
Analysts Estimate Theravance Biopharma (TBPH) to Report a Decline in Earnings: What to Look Out for
Zacks
Feb-11-20 11:05PM  
Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares
PR Newswire -8.80%
02:21PM  
How Does Investing In Theravance Biopharma, Inc. (NASDAQ:TBPH) Impact The Volatility Of Your Portfolio?
Simply Wall St.
Feb-05-20 10:27AM  
Theravance Pipeline Strong, Dependence on Yupelri a Concern
Zacks
Jan-19-20 09:13AM  
3 Strong Buy Biotech Stocks That Can Inject a Healthy Dose of Upside
TipRanks
Jan-07-20 04:48PM  
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
PR Newswire
Dec-24-19 09:16AM  
AstraZeneca's Triple-Combo COPD Inhaler Gets China's Nod
Zacks
Dec-23-19 08:15AM  
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
PR Newswire
Dec-22-19 11:10AM  
Hedge Funds Have Never Been Less Bullish On Theravance Biopharma Inc (TBPH)
Insider Monkey
Dec-10-19 12:22PM  
Seth Klarman Pares Paratek Pharmaceuticals Stake
GuruFocus.com
Dec-05-19 11:31AM  
Theravance Bio (TBPH) Up 25.6% Since Last Earnings Report: Can It Continue?
Zacks
Dec-03-19 07:50AM  
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
PR Newswire
Nov-26-19 04:15PM  
Theravance Biopharma to Present at Two Upcoming Investor Conferences
PR Newswire
Nov-09-19 10:43AM  
Edited Transcript of TBPH earnings conference call or presentation 5-Nov-19 10:00pm GMT
Thomson Reuters StreetEvents
Nov-06-19 04:30PM  
Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference
PR Newswire
11:19AM  
Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates
Zacks
Nov-05-19 06:35PM  
Theravance Biopharma (TBPH) Reports Q3 Loss, Misses Revenue Estimates
Zacks
04:05PM  
Theravance Biopharma, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
PR Newswire
11:24AM  
What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?
Zacks
Oct-29-19 04:15PM  
Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5
PR Newswire
10:32AM  
Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Zacks
Oct-28-19 05:49PM  
Here is What Hedge Funds Think About Theravance Biopharma Inc (TBPH)
Insider Monkey
Oct-21-19 04:00PM  
Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting
PR Newswire
Oct-07-19 10:25AM  
Theravance Pipeline Strong, Dependence on Yupelri a Concern
Zacks
Oct-02-19 01:34PM  
Have Insiders Been Selling Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares?
Simply Wall St.
07:05AM  
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
Zacks
Sep-25-19 04:05PM  
Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference
PR Newswire
Sep-23-19 01:16PM  
Seth Klarman Further Increases Translate Bio Stake
GuruFocus.com
Sep-10-19 01:58PM  
Baupost's Seth Klarman Dives Further Into Translate Bio
GuruFocus.com +8.88%
11:46AM  
Theravance Announces Positive Early Data on JAK Inhibitor
Zacks
Sep-09-19 07:05AM  
Theravance Biopharma Reports Positive Results from Phase 1 Clinical Trial of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
PR Newswire
Aug-28-19 04:30PM  
Theravance Biopharma to Present at Two Upcoming Investor Conferences
PR Newswire
Aug-12-19 10:47AM  
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
Zacks
Aug-11-19 08:32AM  
How Theravance Biopharma, Inc. (NASDAQ:TBPH) Can Impact Your Portfolio Volatility
Simply Wall St.
Aug-09-19 08:24AM  
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
Zacks
08:06AM  
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
Zacks
Aug-07-19 11:20AM  
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
Zacks
Aug-05-19 09:18AM  
Corcept's (CORT) Earnings & Revenues Miss Estimates in Q2
Zacks
Aug-02-19 05:44PM  
Edited Transcript of TBPH earnings conference call or presentation 31-Jul-19 12:00pm GMT
Thomson Reuters StreetEvents
Aug-01-19 03:37PM  
Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates
Zacks
Jul-31-19 03:27PM  
Theravance Biopharma, Inc. (TBPH) Q2 2019 Earnings Call Transcript
Motley Fool
08:35AM  
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Zacks
07:05AM  
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
PR Newswire
Jul-22-19 08:05AM  
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Oral Presentation at 32nd European Neurology Congress
PR Newswire
Jul-18-19 02:33PM  
New antibiotics desperately needed for rising tide of drug-resistant superbugs
American City Business Journals
Jun-27-19 11:27AM  
How Much Did Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Pocket Last Year?
Simply Wall St.
Jun-25-19 07:42AM  
Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium
MarketWatch
Jun-20-19 09:18AM  
AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod
Zacks
Jun-18-19 09:00AM  
Theravance Biopharma Reports New Data from Phase 2 Study of Ampreloxetine (TD-9855) in Presentation at 2019 International Association of Parkinsonism and Related Disorders (IAPRD) World Congress
PR Newswire
Jun-17-19 03:31PM  
Introducing Theravance Biopharma (NASDAQ:TBPH), The Stock That Slid 54% In The Last Five Years
Simply Wall St.
Jun-15-19 12:38PM  
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Benzinga
Jun-14-19 08:05AM  
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China and Adjacent Territories
PR Newswire
Jun-06-19 09:31AM  
Theravance Bio (TBPH) Down 27.7% Since Last Earnings Report: Can It Rebound?
Zacks
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HAUMANN BRETT KChief Medical OfficerAug 21Sale18.2925,000457,240282,810Aug 24 06:21 PM
WORBOYS PHILIP DSVP, Research & Transl ScienceAug 20Sale18.0017,103307,854333,252Aug 24 06:38 PM
SABESAN VIJAYSVP, Technical OperationsDec 12Sale21.031,02721,598145,253Dec 16 06:09 PM
open in yahoo | open in reuters | open in google
affiliate | advertise | contact | privacy | help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.